Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

66.7%

2 terminated/withdrawn out of 3 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
3(100.0%)
3Total
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04727151Phase 1Terminated

TAC T-cells for the Treatment of HER2-positive Solid Tumors

Role: lead

NCT05862324Phase 1Active Not Recruiting

TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)

Role: lead

NCT03880279Phase 1Withdrawn

Autologous TAC T Cells Targeting CD19 in R/R Large B-Cell Lymphoma

Role: lead

All 3 trials loaded